Abstract: Topical steroid withdrawal syndrome (TSW) is an emerging iatrogenic condition increasingly reported in patients following prolonged topical corticosteroid use, particularly among those with atopic dermatitis (AD). Despite rising awareness, TSW remains controversial and under-recognized due to its lack of formal diagnostic criteria and overlap with poorly controlled AD. In response to the growing demand for guidance, we review a wide range of treatments currently being used or studied for TSW, including pharmacologic therapies, natural products, lifestyle interventions, and alternative approaches such as acupuncture and dietary modifications. While many strategies show benefits, few are supported by rigorous clinical evidence. This article aims to provide clinicians and patients with a reference of existing treatment options, highlight areas of uncertainty, and call for further research into validated, evidence-based therapies for this condition.
Get full access to this article
View all access options for this article.
References
1.
MaskeyAR, SasakiA, SargenM, et al.Breaking the cycle: A comprehensive exploration of topical steroid addiction and withdrawal. Front Allergy. 2025; 6:1547923; doi: 10.3389/falgy.2025.1547923
2.
OrrN, RogersM, SteinA, et al.Reviewing the evidence base for topical steroid withdrawal syndrome in the research literature and social media platforms: An evidence gap map. J Med Internet Res. 2024; 26:e57687; doi: 10.2196/57687
3.
HajarT, LeshemYA, HanifinJM, et al.; (the National Eczema Association Task Force). A systematic review of topical corticosteroid withdrawal (“steroid addic- tion”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015; 72(3):541e9.e2–549.e2.
4.
LioPA. Addressing the challenge of topical steroid withdrawal. Pract Dermatol. 2015:41–42.
5.
ShobnamN, RatleyG, SaksenaS, et al.Topical steroid withdrawal is a targetable excess of mitochondrial NAD. J Invest Dermatol. 2025; 145(8):1953–1968.e14; doi: 10.1016/j.jid.2024.11.026
6.
FukayaM, SatoK, SatoM, et al.Topical steroid addiction in atopic dermatitis. Drug Healthc Patient Saf. 2014; 6:131–138; doi: 10.2147/dhps.s6920
7.
RapaportMJ, RapaportV. The red skin syndromes: Corticosteroid addiction and withdrawal. Expert Rev Dermatol. 2006; 1(4):547–561.
CorkMJ, RobinsonDA, VasilopoulosY, et al.New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J Allergy Clin Immunol. 2006; 118(1):3–21; quiz 22-3; doi: 10.1016/j.jaci.2006.04.042
11.
TanSY, ChandranNS, ChoiEC. Steroid phobia: Is there a basis? A review of topical steroid safety, addiction and withdrawal. Clin Drug Investig. 2021; 41(10):835–842; doi: 10.1007/s40261-021-01072-z
RapaportMJ, LebwohlM. Corticosteroid addiction and withdrawal in the atopic: The red burning skin syndrome. Clin Dermatol. 2003; 21(3):201–214; doi: 10.1016/s0738-081x(02)00365-6
14.
FeschukAM, PrattME. Topical steroid withdrawal syndrome in a mother and son: A case report. SAGE Open Med Case Rep. 2023; 11:2050313X231164268; doi: 10.1177/2050313X231164268
15.
JeongHW, HsuKC, LeeJW, et al.Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009; 296(4):E955–E64; doi: 10.1152/ajpendo.90599.2008
16.
LiZ, GengYN, JiangJD, et al.Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014; 2014:289264; doi: 10.1155/2014/289264
17.
MaskeyAR, KopulosD, KwanM, et al.Berberine inhibits the inflammatory response induced by staphylococcus aureus isolated from atopic eczema patients via the TNF-α/Inflammation/RAGE pathways. Cells. 2024; 13(19):1639; doi: 10.3390/cells13191639
18.
FengX, SuredaA, JafariS, et al.Berberine in cardiovascular and metabolic diseases: From mechanisms to therapeutics. Theranostics. 2019; 9(7):1923–1951; doi: 10.7150/thno.30787
19.
ChanE. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993; 63(4):201–208; doi: 10.1159/000243932
20.
SheaM, GrinichE, SimpsonE. Topical steroid withdrawal treated with ruxolitinib cream. JAAD Case Rep. 2024; 48:5–7; doi: 10.1016/j.jdcr.2024.03.011
21.
PowersCM, VermaH, OrloffJ, et al.Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: A case report. J Dermatolog Treat. 2024; 35(1):2336118; doi: 10.1080/09546634.2024.2336118
22.
OlbrichH, SadikCD, LudwigRJ, et al.Dupilumab in inflammatory skin diseases: A systematic review. Biomolecules. 2023; 13(4):634; doi: 10.3390/biom13040634
23.
ArnoldKA, TreisterAD, LioPA. Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series. JAAD Case Rep. 2018; 4(9):860–862; doi: 10.1016/j.jdcr.2018.06.012
24.
OuZ, ChenC, ChenA, et al.Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. Int Immunopharmacol. 2018; 54:303–310; doi: 10.1016/j.intimp.2017.11.031
25.
UzunS, WangZ, McKnightTA, et al.Improvement of skin lesions in corticosteroid withdrawal-associated severe eczema by multicomponent traditional Chinese medicine therapy. Allergy Asthma Clin Immunol. 2021; 17(1):68; doi: 10.1186/s13223-021-00555-0
26.
JayaprakasamB, YangN, WenMC, et al.Constituents of the anti-asthma herbal formula ASHMI(TM) synergistically inhibit IL-4 and IL-5 secretion by murine Th2 memory cells, and eotaxin by human lung fibroblasts in vitro. J Integr Med. 2013; 11(3):195–205; doi: 10.3736/jintegrmed2013029
27.
KimEK, KimEY, MoonPD, et al.Lithospermi radix extract inhibits histamine release and production of inflammatory cytokine in mast cells. Biosci Biotechnol Biochem. 2007; 71(12):2886–2892; doi: 10.1271/bbb.70208
28.
HsuC, LioPA, FriedmanOH. Treatment of topical steroid withdrawal syndrome with traditional Chinese medicine: A case series of 5 adults. Journal of Integrative Dermatology. 2025.
29.
VialG, DetailleD, GuigasB. Role of Mitochondria in the Mechanism(s) of Action of Metformin. Front Endocrinol (Lausanne). 2019; 10:294; doi: 10.3389/fendo.2019.00294
JegasothyBV, AckermanCD, TodoS, et al.Tacrolimus (FK 506)–a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992; 128(6):781–785.
35.
BroedersJA, Ahmed AliU, FischerG. Systematic review and meta-analysis of Randomized Clinical Trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. J Am Acad Dermatol. 2016; 75(2):410–419.e3; doi: 10.1016/j.jaad.2016.02.1228
GalliE, FortinaAB, RicciG, et al.Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). Ital J Pediatr. 2022; 48(1):95; doi: 10.1186/s13052-022-01278-7
38.
SidburyR, DavisDM, CohenDE, et al.; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014; 71(2):327–349; doi: 10.1016/j.jaad.2014.03.030
39.
WollenbergA, Christen-ZächS, TaiebA, et al.; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020; 34(12):2717–2744; doi: 10.1111/jdv.16892
40.
MaccaroneMC, MagroG, SolimeneU, et al.From in vitro research to real life studies: An extensive narrative review of the effects of balneotherapy on human immune response. Sport Sci Health. 2021; 17(4):817–835; doi: 10.1007/s11332-021-00778-z
41.
CastelliL, GalassoL, MulèA, et al.Sleep and spa therapies: What is the role of balneotherapy associated with exercise? A systematic review. Front Physiol. 2022; 13:964232; doi: 10.3389/fphys.2022.964232
42.
GeatD, GiovanniniM, BarloccoEG, et al.Characteristics associated with clinical response to Comano thermal spring water balneotherapy in pediatric patients with atopic dermatitis. Ital J Pediatr. 2021; 47(1):91; doi: 10.1186/s13052-021-00971-3
43.
MillerE, MarkiewiczŁ, SalukJ, et al.Effect of short-term cryostimulation on antioxidative status and its clinical applications in humans. Eur J Appl Physiol. 2012; 112(5):1645–1652; doi: 10.1007/s00421-011-2122-x
44.
StanekA, CholewkaA, GadulaJ, et al.Can whole-body cryotherapy with subsequent kinesiotherapy procedures in closed type cryogenic chamber improve BASDAI, BASFI, and some spine mobility parameters and decrease pain intensity in patients with ankylosing spondylitis? Biomed Res Int. 2015; 2015:404259; doi: 10.1155/2015/404259
45.
KhoshnevisS, CraikNK, DillerKR. Cold-induced vasoconstriction may persist long after cooling ends: An evaluation of multiple cryotherapy units. Knee Surg Sports Traumatol Arthrosc. 2015; 23(9):2475–2483; doi: 10.1007/s00167-014-2911-y
46.
LeungDY, NicklasRA, LiJT, et al.Disease management of atopic dermatitis: An updated practice parameter. Joint task force on practice parameters. Ann Allergy Asthma Immunol. 2004; 93(3 (Suppl 2)):S1–S21; doi: 10.1016/s1081-1206(10)61385-3
47.
National Collaborating Centre for Women’s and Children’s Health (UK). Atopic Eczema in Children: Management of Atopic Eczema in Children from Birth up to the Age of 12 Years. RCOG Press: London; 2007.
48.
Catherine Mack CorreaM, NebusJ. Management of patients with atopic dermatitis: The role of emollient therapy. Dermatol Res Pract. 2012; 2012:836931; doi: 10.1155/2012/836931
49.
JinnouchiO, KuwaharaT, IshidaS, et al.Anti-microbial and therapeutic effects of modified Burow’s solution on refractory otorrhea. Auris Nasus Larynx. 2012; 39(4):374–377; doi: 10.1016/j.anl.2011.07.007
50.
LuuLA, FlowersRH, KellamsAL, et al.Apple cider vinegar soaks [0.5%] as a treatment for atopic dermatitis do not improve skin barrier integrity. Pediatr Dermatol. 2019; 36(5):634–639; doi: 10.1111/pde.13888
51.
ElhageKG, St ClaireK, DaveluyS. Acetic acid and the skin: A review of vinegar in dermatology. Int J Dermatol. 2022; 61(7):804–811; doi: 10.1111/ijd.15804
52.
QuanC. The effect of vinegar and tap water on the release of nickel in grade 304 stainless steel cups. Journal of the South Carolina Academy of Science. 2019; 16(2).
53.
FoodD, AdministrationHHS. Skin protectant drug products for over-the-counter human use; final monograph. Final rule. Fed Regist. 2003; 68(107):33362–33381.
54.
GuptaAK, NicolK. The use of sulfur in dermatology. J Drugs Dermatol. 2004; 3(4):427–431.
55.
PaceWE. A benzoyl peroxide-sulfur cream for acne vulgaris. Can Med Assoc J. 1965; 93(6):252–254.
56.
MohsinN, HernandezLE, MartinMR, et al.Acne treatment review and future perspectives. Dermatol Ther. 2022; 35(9):e15719; doi: 10.1111/dth.15719
57.
CulpB, ScheinfeldN. Rosacea: A review. P T. 2009; 34(1):38–45.
58.
MadsenJT, ThormannJ, KerreS, et al.Allergic contact dermatitis to topical metronidazole—3 cases. Contact Dermatitis. 2007; 56(6):364–366; doi: 10.1111/j.1600-0536.2006.01064.x
FischerAH, HaskinA, OkoyeGA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2017; 76(2):309–313.e2; doi: 10.1016/j.jaad.2016.08.001
61.
BarnesHR. Wound care: Fact and fiction about hydrocolloid dressings. J Gerontol Nurs. 1993; 19(6):23–26; doi: 10.3928/0098-9134-19930601-08
62.
ChaoCM, LaiWY, WuBY, et al.A pilot study on efficacy treatment of acne vulgaris using a new method: Results of a randomized double-blind trial with Acne Dressing. J Cosmet Sci. 2006; 57(2):95–105.
63.
PeyravianN, DeoS, DaunertS, et al.Cannabidiol as a novel therapeutic for immune modulation. Immunotargets Ther. 2020; 9:131–140; doi: 10.2147/ITT.S263690
64.
BaswanSM, KlosnerAE, GlynnK, et al.Therapeutic Potential of Cannabidiol (CBD) for skin health and disorders. Clin Cosmet Investig Dermatol. 2020; 13:927–942; doi: 10.2147/CCID.S286411
65.
Wallen-RussellC, Gijsberts-VeensA, Wallen-RussellS. Could modifying the skin microbiome, diet, and lifestyle help with the adverse skin effects after stopping long-term topical steroid use? Allergies. 2021; 2(1):1–15; doi: 10.3390/allergies2010001
66.
PaceTW, NegiLT, AdameDD, et al.Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology. 2009; 34(1):87–98; doi: 10.1016/j.psyneuen.2008.08.011
67.
YuC, ZhangP, LvZT, et al.Efficacy of acupuncture in itch: A systematic review and meta-analysis of clinical randomized controlled trials. Evid Based Complement Alternat Med. 2015; 2015:208690; doi: 10.1155/2015/208690
68.
NapadowV, LiA, LoggiaML, et al.The brain circuitry mediating antipruritic effects of acupuncture. Cereb Cortex. 2014; 24(4):873–882; doi: 10.1093/cercor/bhs363
69.
LiuJ-J, LiX, GuoJ, et al.Role of GRPR in acupuncture intervention in the “Itch-scratch Vicious Cycle” Spinal circuit of chronic pruritus. Chin Med. 2023; 18(1):2; doi: 10.1186/s13020-022-00706-4
70.
ZhangJ, ShangH, GaoX, et al.Acupuncture-related adverse events: A systematic review of the Chinese literature. Bull World Health Organ. 2010; 88(12):915–921C; doi: 10.2471/BLT.10.076737
71.
ŁuczajW, SkrzydlewskaE. Antioxidative properties of black tea. Prev Med. 2005; 40(6):910–918; doi: 10.1016/j.ypmed.2004.10.014
72.
HarfoushA, SwaidanA, KhazaalS, et al.From spent black and green tea to potential health boosters: Optimization of polyphenol extraction and assessment of their antioxidant and antibacterial activities. Antioxidants (Basel). 2024; 13(12):1588; doi: 10.3390/antiox13121588
73.
van den BogaardEH, BergboerJG, Vonk-BergersM, et al.Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013; 123(2):917–927; doi: 10.1172/JCI65642
74.
ZeichnerJA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol. 2010; 3(9):37–40.
75.
MayerB, BrunnerF, SchmidtK. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993; 45(2):367–374; doi: 10.1016/0006-2952(93)90072-5
76.
GanL, JiangJ, DuanJW, et al.Cold atmospheric plasma applications in dermatology: A systematic review. J Biophotonics. 2021; 14(3):e202000415; doi: 10.1002/jbio.202000415
77.
LandscheidtK, EngelhardtC, HernekampJF, et al.Use of cold plasma in wound healing: A case report. Adv Skin Wound Care. 2022; 35(12):1–3; doi: 10.1097/01.ASW.0000891084.22486.a7
78.
BuscoG, RobertE, Chettouh-HammasN, et al.The emerging potential of cold atmospheric plasma in skin biology. Free Radic Biol Med. 2020; 161:290–304; doi: 10.1016/j.freeradbiomed.2020.10.004
79.
BranýD, DvorskáD, HalašováE, et al.Cold atmospheric plasma: A powerful tool for modern medicine. Int J Mol Sci. 2020; 21(8):2932; doi: 10.3390/ijms21082932
80.
Eyelid dermatitis to red face syndrome to cure: Clinical experience in 100 cases Rapaport, Marvin J. et al. J Am Acad Dermatol.;41(3):435–442.
81.
FukayaM, SatoK, YamadaT, et al.A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period. Clin Cosmet Investig Dermatol. 2016; 9:151–158.
82.
ShearyB, HarrisMF. Cessation of long-term topical steroids in adult atopic dermatitis: A prospective cohort study. Dermatitis. 2020; 31(5):316–320.
83.
HodgeBD, HuynhTN, BrodellRT. “Folly” à deux: Topical corticosteroid addiction in mother and son. JAAD Case Rep. 2019; 5(1):82–85.
84.
BartaK, FonacierLS, HartM, et al.Corticosteroid exposure and cumulative effects in patients with eczema: Results from a patient survey. Ann Allergy Asthma Immunol. 2023; 130(1):93–99.e10; doi: 10.1016/j.anai.2022.09.031
